fda warning glp-1 compounding september 2025 Concerns Surrounding Compounded GLP-1s Mount As Shortages of Tirzepatide, Semaglutide End FDA is moving to restrict

Higher doses can trigger inhibitory feedback

That can include muscle, water, glycogen, connective tissue, and other non-fat tissue

The exact peptides involved are unknown

But they work in totally different ways: Sermorelin therapy: stimulates the pituitary gland to release growth hormone, which increases IGF-1 and supports bone, muscle, and metabolic function Estrogen therapy: binds to estrogen receptors rather than growth hormone receptors, impacting many of the same tissues, including bones, muscles, and fat As women balance the symptoms that arise during perimenopause and midlife, finding the right solution varies based on personal needs, body type, and other health factors

So, as ICD-10 does not assign a specific Z79 code to injectable non-insulin antidiabetic drugs, it would be correct to assign Z79.899 to them to document their current, long-term use

Medication Interactions and Current Prescriptions That Matter GLP-1 drugs interact significantly with insulin and sulfonylurea diabetes medications, which increase hypoglycemia risk when combined